enGene director receives 31,000 stock options
enGene Therapeutics Inc. director Lota S. Zoth reported receiving a grant of stock options covering 31,000 common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
enGene Therapeutics Inc. director Lota S. Zoth reported receiving a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
According to the terms, the entire option award vests on the earlier of the first anniversary of the vesting commencement date of June 9, 2026 or the company’s 2027 annual meeting of shareholders. After this grant, Zoth holds 31,000 stock options directly.
Insider Trade Summary
Grant/Award: 31,000 shares
Grant/Award
1 txn
Insider
Zoth Lota S.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 31,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 31,000 contracts (Direct)
Footnotes (1)
- F1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.
Key Figures
Options granted: 31,000 options
Exercise price: $1.75 per share
Grant price: $0.00 per option
+3 more
6 metrics
Options granted
31,000 options
Stock Option (Right to Buy) granted to director on June 16, 2026
Exercise price
$1.75 per share
Conversion or exercise price of stock options
Grant price
$0.00 per option
Options awarded at no cost to the director
Expiration date
June 16, 2036
Option expiration date for the 31,000 options
Holdings after grant
31,000 options
Total stock options held directly following this transaction
Vesting trigger
Earlier of June 9, 2027 or 2027 meeting
First anniversary of June 9, 2026 vesting start or 2027 annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, vesting commencement date, annual meeting of shareholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.7500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement date financial
"the vesting commencement date, which was June 9, 2026"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
derivative security financial
"transaction_type: "derivative" for the stock option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did enGene Therapeutics (ENGN) report for Lota S. Zoth?
enGene Therapeutics reported that director Lota S. Zoth received a grant of stock options for 31,000 common shares. These options were granted at no cost and give the right to buy shares at a fixed exercise price of $1.75 per share.
What are the key terms of Lota S. Zoth’s 31,000 enGene Therapeutics stock options?
The grant covers 31,000 stock options with an exercise price of $1.75 per share. The options were granted for no cash payment and expire on June 16, 2036, giving a long time frame in which they can potentially be exercised.
When do Lota S. Zoth’s enGene Therapeutics stock options vest?
The options vest fully on the earlier of the first anniversary of the vesting commencement date of June 9, 2026 or enGene Therapeutics’ 2027 annual meeting of shareholders. This single vesting date means the entire 31,000-option grant becomes exercisable at once.
How many enGene Therapeutics options does Lota S. Zoth hold after this Form 4 filing?
Following this reported transaction, Lota S. Zoth holds 31,000 stock options in enGene Therapeutics directly. These options each relate to one common share and carry an exercise price of $1.75 per share, according to the Form 4 disclosure details.
Is Lota S. Zoth’s enGene Therapeutics option grant an open-market purchase or compensation award?
The transaction is classified as a grant or award, not an open-market purchase. The options were awarded at a price of $0.00 per option, with an exercise price of $1.75, indicating compensation-related equity rather than a market trade.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates